Artículos relacionados
Foundayo
Eli Lilly oral obesity treatment whose active ingredient is orforglipron; marketed in the U.S. since April and the UK since August, with European arrival expected soon after a favorable EMA opinion in mid-October.
Artículos relacionados
Eli Lilly oral obesity treatment whose active ingredient is orforglipron; marketed in the U.S. since April and the UK since August, with European arrival expected soon after a favorable EMA opinion in mid-October.